Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marqibo in Relapsed/Refractory Aggressive NHL
NCT00006383Phase 2Completed
- Sponsor
- Inex Pharmaceuticals Corporation
- Start
- Jun 2000
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of vincristine sulfate liposome in non-Hodgkin lymphoma (NHL), sponsored by Inex Pharmaceuticals Corporation. Primary endpoint: Objective Response Rate. Started Jun 2000; status: completed.
02
Drugs
vincristine sulfate liposome
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00006383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006383.